The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Micro-neutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.

Euro Surveill
Zuckerman N, Nemet I, Kliker L, Atari N, Lustig Y, Bucris E, Bar Ilan D, Geva M, Sorek-Abramovich R, Weiner C, Rainy N, Bar-Chaim A, Benveniste-Levkovitz P, Abu Hamed R, Regev-Yochay G, Hevkin O, Mor O, Alroy-Preis S, Mendelson E, Mandelboim M.
doi: 10.2807/1560-7917.ES.2021.26.45.2100974